Compare AbCellera Biologics Inc (ABCL) vs Badger Meter Inc (BMI) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Badger Meter (BMI) trades at $149.79, up 2.69% with a bullish technical signal from moving averages. The company maintains strong profitability with 14.56% net income margin and 19.6% ROE, though recent earnings misses and a securities class action lawsuit create headwinds. Valuation metrics show a P/E of 33.89 and P/S of 4.93, above industry averages.

While BMI demonstrates solid fundamentals and technical strength, the stock faces significant legal risks from multiple class action lawsuits alleging securities fraud. Analyst consensus is mixed with 28% buy ratings but a $144.80 price target below current levels. The combination of legal overhang and premium valuation creates a cautious near-term outlook despite strong operational performance.